Search the Studies

122 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
000792-CA Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults with B Lineage Acute LymphoblaRecruitment has not started1-25 YearsNCI Leukemia T-Cell
000631-CInvestigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell TherapyRecruitment has not started5-125 YearsNCI Leukemia T-Cell
000324-CPhase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-35 YearsNCI Leukemia T-Cell
000067-CUnderstanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell TherapyParticipants currently recruited/enrolled2-125 YearsNCI Leukemia T-Cell
20-C-0011Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary SyndromeCompleted Study; data analyses ongoing18-125 YearsNCI Leukemia T-Cell
19-C-0076A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell MalignanciesCompleted Study; data analyses ongoing18-125 YearsNCI Leukemia T-Cell
17-C-0137Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by Invitation3-65 YearsNCI Leukemia T-Cell
16-C-0062A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)Completed Study; data analyses ongoing18-125 YearsNCI Leukemia T-Cell
16-C-0061Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsParticipants currently recruited/enrolled18-125 YearsNCI Leukemia T-Cell
15-H-0172A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)No longer recruiting/follow-up only18-125 YearsNHLBILeukemia T-Cell
15-C-0141Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell StudiesEnrolling by Invitation18-125 YearsNCI Leukemia T-Cell
13-N-0135Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)Completed Study; data analyses ongoing18-125 YearsNINDSLeukemia T-Cell
13-C-0006Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Smoldering and Chronic Adult T-cell Leukemia (ATL)Completed Study; data analyses ongoing18-125 YearsNCI Leukemia T-Cell
12-C-0193Lymphoid Malignancies and Precursors: Tissue Acquisition ProtocolParticipants currently recruited/enrolled18-125 YearsNCI Leukemia T-Cell
09-C-0025Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Leukemia T-Cell
05-H-0242A Pilot Study of Alemtuzumab (Campath) in Patients with Relapsed or Refractory Severe Aplastic AnemiaCompleted Study; data analyses ongoing2-110 YearsNHLBILeukemia T-Cell
000975-CCollection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples from Healthy Volunteers Used for Comparative Analysis of Myeloid MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
000923-HObservational Study of Cardiac Arrhythmias in Subjects Treated with BTK InhibitorsParticipants currently recruited/enrolled18-110 YearsNHLBILeukemia
000867-CCHumanitarian Use Device (HUD) Protocol for Use of Miltenyi CliniMACS (Registered Trademark) CD34 Reagent System in AMLParticipants currently recruited/enrolled0-125 YearsCC Leukemia
000821-IAn Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 LymphopeniaRecruitment has not started18-75 YearsNIAIDT-Cell
000732-CA Long-Term Follow-Up Study of Patients Who Received VOR33Recruitment has not started18-125 YearsNCI Leukemia
000731-CA First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell TransplantationParticipants currently recruited/enrolled18-70 YearsNCI Leukemia
000661-CComprehensive Molecular and Clinical Evaluation of Pediatric and Adult Myelodysplastic Syndromes (MDS)Participants currently recruited/enrolled0-125 YearsNCI Leukemia
000633-CPhase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI T-Cell
000613-CPhase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood StParticipants currently recruited/enrolled12-125 YearsNCI Leukemia
000509-CAn Open Label, Multi-Center Roll-Over Study to Assess Long-Term Safety in Patients Who are Ongoing or Have Completed a Prior Global Novartis or GSK Sponsored Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Study and are Judged by the Investigator to BEnrolling by Invitation18-125 YearsNCI Leukemia
000489-CPhase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic MalignanciesClinical hold/Recruitment or enrollment suspended12-125 YearsNCI Leukemia
000464-HEvaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative TherapiesEnrolling by Invitation4-125 YearsNHLBILeukemia
000444-HVaccine Responses in Patients with B Cell MalignanciesParticipants currently recruited/enrolled18-125 YearsNHLBILeukemia
000326-HA Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell MalignanciesParticipants currently recruited/enrolled18-125 YearsNHLBILeukemia
000193-CPhase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell LymphomasClinical hold/Recruitment or enrollment suspended18-125 YearsNCI T-Cell
000124-CA Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic LeukemiaRecruitment has not started2-21 YearsNCI Leukemia
000115-CA Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster DParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
000114-CA Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated with Androgen Deprivation TherapyParticipants currently recruited/enrolled18-125 YearsNCI T-Cell
21-C-0019Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and VariantParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-H-0044Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in PsoriasisCompleted Study; data analyses ongoing18-80 YearsNHLBIT-Cell
20-H-0033Early Initiation of Oral Therapy with Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)Participants currently recruited/enrolled3-125 YearsNHLBIT-Cell
20-H-0016Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Completed Study; data analyses ongoing18-125 YearsNHLBILeukemia
20-C-0162A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-C-0127A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignanciesParticipants currently recruited/enrolled18-125 YearsNCI T-Cell
20-C-0103Investigation of the B- and T-cell Repertoire and Immune Response in Patients with Acute and Resolved COVID-19 InfectionParticipants currently recruited/enrolled18-125 YearsNCI T-Cell
20-C-0098A Phase 1/2, Open Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects with Advanced or Metastatic Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI T-Cell
20-C-0076Phase 2 Trial of Encorafenib plus Binimetinib for Patients with BRAF V600 Mutated Relapsed/Refractory HCLParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-C-0075Phase 2 Trial for Binimetinib for Patients with Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
20-C-0070A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients with Inborn Errors of ImmunityParticipants currently recruited/enrolled4-69 YearsNCI T-Cell
20-C-0041Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic InjuriesEnrolling by Invitation1-125 YearsNCI T-Cell
20-C-0028Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid LeukemiaParticipants currently recruited/enrolled3-35 YearsNCI Leukemia
19-I-0015Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-lymphocyte Antigen 4 (CTLA4) HaploinsufficiencyParticipants currently recruited/enrolled8-65 YearsNIAIDT-Cell
19-HG-0059Longitudinal Studies of Patients with FPDMMParticipants currently recruited/enrolled0-125 YearsNHGRILeukemia
19-H-0111Early Clonal Dynamics During Venetoclax Treatment for Chronic Lymphocytic Leukemia (CLL)Participants currently recruited/enrolled18-125 YearsNHLBILeukemia
19-H-0001Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Na(SqrRoot) ve or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) TherapyNo longer recruiting/follow-up only18-125 YearsNHLBILeukemia
19-C-0143A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic CancerParticipants currently recruited/enrolled18-70 YearsNCI T-Cell
19-C-0117A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing CancerParticipants currently recruited/enrolled18-120 YearsNCI T-Cell
19-C-0112Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic MalignanciesParticipants currently recruited/enrolled12-125 YearsNCI Leukemia
19-C-0102A Phase I Clinical Trial of T-cells Expressing an anti-SLAMF7 CAR for Treating Multiple MyelomaCompleted Study; data analyses ongoing18-73 YearsNCI T-Cell
19-C-0085Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell LymphomaClinical hold/Recruitment or enrollment suspended12-125 YearsNCI T-Cell
19-C-0042A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Leukemia
19-C-0017A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsParticipants currently recruited/enrolled18-70 YearsNCI T-Cell
18-I-0041Investigating the Mechanistic Biology of Primary Immunodeficiency DisordersParticipants currently recruited/enrolled0-75 YearsNIAIDT-Cell
18-CC-0013A Randomized, Double-Blind, Placebo-Controlled Study of a Single Dose of Pembrolizumab in HIV-Infected PatientsParticipants currently recruited/enrolled18-99 YearsCC T-Cell
18-C-0135Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationParticipants currently recruited/enrolled4-125 YearsNCI T-Cell
18-C-0080Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled TrialCompleted Study; data analyses ongoing5-125 YearsNCI Leukemia
18-C-0059Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Leukemia
18-C-0049A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic CancerParticipants currently recruited/enrolled18-72 YearsNCI T-Cell
18-C-0026A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)Participants currently recruited/enrolled1-21 YearsNCI Leukemia
17-H-0118A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)No longer recruiting/follow-up only18-125 YearsNHLBILeukemia
17-H-0026Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid LeukemiaCompleted Study; data analyses ongoing18-99 YearsNHLBILeukemia
17-C-0113A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsParticipants currently recruited/enrolled18-70 YearsNCI T-Cell
17-C-0092A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal CancerCompleted Study; data analyses ongoing18-125 YearsNCI T-Cell
17-C-0048Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell LymphomasCompleted Study; data analyses ongoing18-73 YearsNCI T-Cell
17-C-0028A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo ) in Combination with Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic LeukemiaCompleted Study; data analyses ongoing2-21 YearsNCI Leukemia
16-N-0072A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-cellsCompleted Study; data analyses ongoing18-125 YearsNINDST-Cell
16-H-0085Pilot Study to Evaluate the Effect of Fasting and Refeeding on T-Cell FateCompleted Study; data analyses ongoing21-37 YearsNHLBIT-Cell
16-C-0131A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing CancersParticipants currently recruited/enrolled18-70 YearsNCI T-Cell
16-C-0066Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmParticipants currently recruited/enrolled18-125 YearsNCI T-Cell
16-C-0054T Cells Expressing a Fully-human Anti- CD19 Chimeric Antigen Receptor for Treating B-cell MalignanciesNo longer recruiting/follow-up only18-73 YearsNCI T-Cell
16-C-0003Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesParticipants currently recruited/enrolled4-75 YearsNCI T-Cell
15-H-0016A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.No longer recruiting/follow-up only18-125 YearsNHLBILeukemia
15-C-0093Phase I Trial of Turalio(R) (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)Participants currently recruited/enrolled3-35 YearsNCI Leukemia
15-C-0076A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139Completed Study; data analyses ongoing18-125 YearsNCI T-Cell
15-C-0067A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
15-C-0029Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell MalignanciesParticipants currently recruited/enrolled3-39 YearsNCI Leukemia
14-HG-0048Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)Participants currently recruited/enrolled21-125 YearsNHGRIT-Cell
14-C-0131A Phase II, Open-Label Study in Patients With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and TrametinibCompleted Study; data analyses ongoing18-125 YearsNCI Leukemia
14-C-0056Collection of Blood from Patients with Ovarian, Primary Peritoneal or Fallopian Tube CancerCompleted Study; data analyses ongoing18-125 YearsNCI T-Cell
14-C-0004A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Leukemia
13-I-0157The Natural History of GATA2 Deficiency and Related DisordersParticipants currently recruited/enrolled2-100 YearsNIAIDLeukemia
13-H-0116A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult PatientsParticipants currently recruited/enrolled4-125 YearsNHLBILeukemia
13-C-0132Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC SyndromeParticipants currently recruited/enrolled8-70 YearsNCI Leukemia
13-C-0095A Phase 2 Study of GI-6207 in Patients with Recurrent Medullary Thyroid CancerCompleted Study; data analyses ongoing18-125 YearsNCI T-Cell
12-H-0035A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p DeletionNo longer recruiting/follow-up only18-125 YearsNHLBILeukemia
12-C-0160Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Adults with Chronic Illness and their ParentsParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
12-C-0112Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell MalignanciesCompleted Study; data analyses ongoing1-30 YearsNCI Leukemia
11-I-0007Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined ImmunodeficiencyClinical hold/Recruitment or enrollment suspended2-40 YearsNIAIDLeukemia
11-C-0255Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni SyndromeParticipants currently recruited/enrolled0-125 YearsNCI Leukemia
11-C-0242Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug DispositionParticipants currently recruited/enrolled3-125 YearsNCI Leukemia
11-C-0136Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging EvaluationCompleted Study; data analyses ongoing2-55 YearsNCI Leukemia
10-H-0154Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-CellsParticipants currently recruited/enrolled4-80 YearsNHLBIT-Cell
10-H-0141A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.No longer recruiting/follow-up only18-99 YearsNHLBILeukemia
10-C-0086Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological StudiesParticipants currently recruited/enrolled0-125 YearsNCI Leukemia
10-C-0066A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer TreatmentParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
10-C-0054Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell TransplantationNo longer recruiting/follow-up only18-75 YearsNCI Leukemia
10-C-0025Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
09-H-0199A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R agonist), Eltrombopag, in Patients with Low to Int-2 Risk Myelodysplastic Syndrome (MDS)Completed Study; data analyses ongoing18-125 YearsNHLBILeukemia
09-C-0053Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow DonEnrolling by Invitation1-125 YearsNCI Leukemia
09-C-0005Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual DiseaseParticipants currently recruited/enrolled18-125 YearsNCI Leukemia
08-H-0186Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with BortezomibCompleted Study; data analyses ongoing18-70 YearsNHLBILeukemia
08-H-0105Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)Participants currently recruited/enrolled18-125 YearsNHLBILeukemia
07-C-0195Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the TreaCompleted Study; data analyses ongoing18-74 YearsNCI Leukemia
06-I-0015Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell DeathParticipants currently recruited/enrolled0-125 YearsNIAIDT-Cell
06-H-0190Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)Completed Study; data analyses ongoing18-85 YearsNHLBILeukemia
06-C-0150A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell LeukemiaNo longer recruiting/follow-up only18-125 YearsNCI Leukemia
05-H-0130Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell TransplantsParticipants currently recruited/enrolled7-80 YearsNHLBILeukemia
04-C-0102Hematologic Malignancy Biology StudyEnrolling by Invitation1-75 YearsNCI Leukemia
02-I-0286Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic SyndromeParticipants currently recruited/enrolled2-125 YearsNIAIDLeukemia
02-H-0250A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1HCompleted Study; data analyses ongoing18-125 YearsNHLBILeukemia
02-C-0210Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node MalignancyParticipants currently recruited/enrolled0-125 YearsNCI Leukemia
02-C-0179Biospecimen Acquisition from Human SubjectsParticipants currently recruited/enrolled18-125 YearsNCI T-Cell
99-H-0050Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic DiseasesCompleted Study; data analyses ongoing2-80 YearsNHLBILeukemia
98-N-0047Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP)Participants currently recruited/enrolled18-125 YearsNINDSLeukemia
96-H-0049Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections from Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic TransplantationParticipants currently recruited/enrolled18-60 YearsNHLBILeukemia
94-C-0074Treatment and Natural History Study of Lymphomatoid GranulomatosisParticipants currently recruited/enrolled12-125 YearsNCI Leukemia
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®